UNCY NASDAQ
Unicycive Therapeutics, Inc.
1W: -5.4%
1M: +4.0%
3M: +21.4%
YTD: +33.3%
1Y: +29.7%
3Y: -44.0%
$7.74
+0.01 (+0.13%)
After Hours: $7.82 (+0.08, +1.03%)
Weekly Expected Move ±7.5%
$7
$8
$8
$9
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$166.1M
52W Range3.71-11
Volume597,599
Avg Volume526,840
Beta1.77
Dividend—
Analyst Ratings
Company Info
CEOShalabh K. Gupta
Employees22
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-12
Websiteunicycive.com
4300 El Camino Real
Los Altos, CA 94022
US
Los Altos, CA 94022
US
650 351 4495
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Latest News
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
[10-Q] Unicycive Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Brookline Capital Markets Forecasts UNCY Q1 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of “Moderate Buy” by Brokerages
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Jermasek Douglas | A-Award | 169,500 | — | 2026-05-14 |
| Gupta Pramod | A-Award | 169,500 | — | 2026-05-14 |
| Townsend John | A-Award | 169,500 | — | 2026-05-14 |
| Laumas Sandeep | A-Award | 84,200 | — | 2026-05-14 |
| Laumas Sandeep | A-Award | 42,100 | — | 2026-05-14 |